Abstract
Biological therapies have transformed the management of inflammatory bowel disease (IBD) and other immune-mediated conditions. However, their immunosuppressive nature raises concerns regarding the reactivation of tuberculosis (TB). This population-based study in Hong Kong investigated the incidence of TB among patients treated with various biologics between 2006 and 2015. Analyzing 2,485 patients, the study found a significantly elevated risk of TB across all treated groups, with the highest risk observed in patients with IBD and those specifically treated with infliximab. These findings underscore the necessity of careful patient and drug selection in clinical practice.
Introduction
The advent of biological therapies, particularly tumor necrosis factor-alpha (TNF-α) inhibitors, has revolutionized the treatment landscape for chronic inflammatory conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD). Despite their efficacy, these agents are known to modulate immune responses, potentially increasing susceptibility to opportunistic infections. Tuberculosis (TB) remains a significant global health concern, and the risk of its reactivation or new infection in patients on biologics is a critical safety consideration.
While clinical trials provide initial safety data, they often lack the scale or environmental context to capture real-world epidemiological trends, especially in regions where TB is endemic. This study aimed to quantify the incidence of TB in a population-based cohort in Hong Kong, comparing risks across different immune-mediated diseases and specific biological agents.
Methodology
This retrospective study utilized a territory-wide computerized database managed by the Hong Kong Hospital Authority, covering a study period from 2006 to 2015. The cohort included 2,485 patients diagnosed with immune-mediated diseases, categorized into three primary groups:
- Rheumatology: 77.7%
- Dermatology: 11.8%
- Inflammatory Bowel Disease (IBD): 10.6%
Researchers tracked patient demographics, specific biological prescriptions, and the occurrence of active TB infections over a total of 6,921 person-years of follow-up. The primary metrics used were Incidence Rates (IRs) and Standardized Incidence Ratios (SIRs), the latter of which compared the observed TB cases in the cohort to expected cases in the general population, adjusted for age and sex. Subgroup analyses were further conducted to determine the hazard ratios (HR) between different biological drugs, including infliximab, etanercept, and adalimumab.
Results
Overall and Disease-Specific Risk
During the follow-up period (median duration of 748 days), 54 subjects developed active TB. The overall SIR for TB among patients on biological therapy was 10.91, indicating a nearly 11-fold increase in risk compared to the general population.
When stratified by disease type, patients with IBD exhibited the highest vulnerability, with an SIR of 17.53. Despite this high ratio, subgroup analysis indicated that once adjusted for treatment types, there was no statistically significant difference in the risk of TB between the IBD, rheumatology, and dermatology cohorts, suggesting that the biological treatment itself is the primary driver of risk rather than the underlying disease pathology.
Drug-Specific Risk
The study identified significant variations in risk based on the specific biologic agent administered:
- Infliximab: Associated with the highest risk, yielding an SIR of 25.95.
- Comparative Hazard: Infliximab was found to be significantly riskier than other TNF-α inhibitors, with a hazard ratio (HR) of 4.10 compared to etanercept and 2.08 compared to adalimumab.
Demographic Trends
Age was a significant factor in TB incidence. The highest risk was observed in the 50–59 age group, which reached an SIR of 15.72. The mean age of patients who developed TB in the study was 43 years.
Discussion
The findings highlight a substantial increase in TB risk for patients undergoing biological therapy in Hong Kong. The nearly 26-fold risk associated with infliximab is particularly noteworthy for clinicians. This disparity between agents—specifically the higher risk of infliximab compared to etanercept and adalimumab—may be attributed to the different molecular structures and mechanisms of action of these drugs, which affect TNF-α signaling and granuloma maintenance differently.
While the study provides robust population-based data, it is important to note certain limitations. The abstract does not specify the baseline screening protocols for latent TB infection (LTBI) used during the study period. In regions like Hong Kong, where TB is more prevalent, the effectiveness of pre-treatment screening and prophylactic therapy is a critical variable in preventing reactivation. Furthermore, the results are most directly applicable to regions with similar TB endemicity.
Conclusion
Biological therapy is associated with a markedly higher risk of tuberculosis in patients with immune-mediated diseases compared to the general population. Infliximab carries the highest risk among the biologics studied, particularly for patients with IBD and those in middle-age brackets. These results suggest that clinical decisions should prioritize rigorous TB screening and careful selection of biological agents to balance therapeutic benefits with the risk of serious infection.
Summary updated